Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Acumen Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference By: Acumen Pharmaceuticals, Inc. via GlobeNewswire January 04, 2024 at 16:15 PM EST CHARLOTTESVILLE, Va., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will present at the 42nd Annual J.P. Morgan Healthcare Conference taking place in San Francisco on Thursday, January 11, 2024, at 10:30 a.m. PT (1:30 p.m. ET). The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days. About Acumen Pharmaceuticals, Inc. Acumen, headquartered in Charlottesville, VA, with additional offices in Indianapolis, IN and Newton, MA, is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, ACU193, a humanized monoclonal antibody that selectively targets toxic soluble AβOs, following positive topline results in INTERCEPT-AD, a Phase 1 clinical trial involving early Alzheimer’s disease patients. For more information, visit www.acumenpharm.com. Investors: Alex Braunabraun@acumenpharm.com Media: AcumenPR@westwicke.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Acumen Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference By: Acumen Pharmaceuticals, Inc. via GlobeNewswire January 04, 2024 at 16:15 PM EST CHARLOTTESVILLE, Va., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will present at the 42nd Annual J.P. Morgan Healthcare Conference taking place in San Francisco on Thursday, January 11, 2024, at 10:30 a.m. PT (1:30 p.m. ET). The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days. About Acumen Pharmaceuticals, Inc. Acumen, headquartered in Charlottesville, VA, with additional offices in Indianapolis, IN and Newton, MA, is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, ACU193, a humanized monoclonal antibody that selectively targets toxic soluble AβOs, following positive topline results in INTERCEPT-AD, a Phase 1 clinical trial involving early Alzheimer’s disease patients. For more information, visit www.acumenpharm.com. Investors: Alex Braunabraun@acumenpharm.com Media: AcumenPR@westwicke.com
CHARLOTTESVILLE, Va., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will present at the 42nd Annual J.P. Morgan Healthcare Conference taking place in San Francisco on Thursday, January 11, 2024, at 10:30 a.m. PT (1:30 p.m. ET). The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days. About Acumen Pharmaceuticals, Inc. Acumen, headquartered in Charlottesville, VA, with additional offices in Indianapolis, IN and Newton, MA, is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, ACU193, a humanized monoclonal antibody that selectively targets toxic soluble AβOs, following positive topline results in INTERCEPT-AD, a Phase 1 clinical trial involving early Alzheimer’s disease patients. For more information, visit www.acumenpharm.com. Investors: Alex Braunabraun@acumenpharm.com Media: AcumenPR@westwicke.com